Clinical trials: Solitary Bone Plasmacytoma
Multiple Myeloma, Solitary Plasmacytoma
MargheRITA (Remote Intelligence for Therapeutic Adherence)
It is essential to improve clinical efficiency and management of hematological and oncological patients treated on an outpatient basis.
- Conditions
- Multiple Myeloma, Solitary Plasmacytoma, Amyloidosis, Chronic Myeloid Leukemia
- Trial name
- MargheRITA (NCT05260203)
- Testing
- RITA (App)
- Where
- Italy
- Volunteers
- 124 people
- Sponsor
- Advice Pharma Group srl
Chronic Myeloproliferative Disorders, Fever, Sweats, and Hot Flashes
Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer
RATIONALE: Antibiotics such as amoxicillin, ciprofloxacin, and moxifloxacin may be effective in preventing or controlling fever and neutropenia in patients with cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Fever, Sweats, and Hot Flashes, Infection, Leukemia
- Trial name
- NCT00062231
- Testing
- amoxicillin-clavulanate potassium, ciprofloxacin, moxifloxacin hydrochloride
- Where
- 23 sites in Belgium, France and 6 more
- Volunteers
- 351 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Plasmacytoma
Stereotactic Body Radiotherapy for the Treatment of Solitary Bone Plasmacytoma
This project aims to propose a new approach in the treatment of solitary plasmacytoma: hypofractionated irradiation alone with stereotactic technique that may contribute to the successful treatment of this disease.
- Trial name
- NCT03312868
- Testing
- SBRT
- Where
- Brazil
- Volunteers
- 10 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Solitary Bone Plasmacytoma, Plasmacytoma of Bone
Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration
This is a prospective, single-arm, single-center clinical trial designed to evaluate the safety and efficacy of radiation combined with a BCMA/CD3 bispecific antibody (CM336) in patients with solitary bone plasmacytoma (SBP) with…
- Conditions
- Solitary Bone Plasmacytoma, Plasmacytoma of Bone, Plasma Cell Disorders
- Trial name
- NCT07115667
- Testing
- BCMA/CD3 bispecific antibody (CM336)
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma, Plasmacytoma
S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI) and fludeoxyglucose F 18 positron emission tomography (^18FDG-PET) may help diagnose solitary plasmacytoma.
- Trial name
- NCT00109889
- Testing
- magnetic resonance imaging, positron emission tomography
- Where
- 26 sites in United States
- Volunteers
- 2 people
- Sponsor
- SWOG Cancer Research Network
Plasmacytoma
Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma
The purpose of the trial is to establish whether adjuvant therapy with lenalidomide + dexamethasone after radiotherapy can improve progression free survival in patients with high risk solitary bone plasmacytoma compared with RT…
- Trial name
- IDRIS (NCT02544308)
- Testing
- Lenalidomide, Dexamethasone, No further treatment
- Where
- 13 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- University College, London
Solitary Plasmacytoma
SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial
Solitary Plasmacytoma (SP) is a rare malignant plasma cell tumor, including Solitary Bone Plasmacytoma (SBP) and Solitary Extramedullary Plasmacytoma (SEP). Radiotherapy is the preferred treatment for SP.
- Trial name
- NCT06863584
- Testing
- Lenalidomide (Revlimid), SBRT
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Solitary Bone Plasmacytoma
A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma
This study is being done to evaluate whether the combination of immune therapy and radiation therapy to plasmacytoma that can stimulate the immune system to attack and eliminate the abnormal cells in the bone marrow and perhaps…
- Trial name
- NCT03196401
- Testing
- Durvalumab, Radiation therapy
- Where
- 6 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solitary Plasmacytoma
Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma
Solitary plasmacytoma (SP) is characterized by a localized mass of clonal plasma cells with no or minimal bone marrow plasmacytosis. It can present either as EMP or SBP.
- Trial name
- NCT05248633
- Testing
- radiotherapy, Bortezomib Injection, Lenalidomide
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Peking Union Medical College Hospital
Solitary Osseous Plasmacytoma
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone
This randomized phase III trial compares ixazomib citrate, lenalidomide, dexamethasone and zoledronic acid with zoledronic acid alone to see how well they work when given after radiation therapy in treating patients with solitary…
- Trial name
- NCT02516423
- Testing
- ixazomib, lenalidomide, dexamethasone
- Where
- 388 sites in United States
- Volunteers
- 11 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
This phase II trial investigates whether patients greater than or equal to 65 years of age diagnosed with myeloma or another plasma cell malignancy will have better outcomes with transplant followed by maintenance therapy, as…
- Conditions
- Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease, Primary Systemic Amyloidosis
- Trial name
- NCT01849783
- Testing
- dexamethasone, cisplatin, doxorubicin
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Margarida Magalhaes-Silverman
Multiple Myleoma
GR1803 Injection in Patients With RRMM
All subjects will receive GR1803 injection until intolerable toxicity or investigator-assessed disease progression occurs (except in cases of disease progression due to discontinuation of the drug as a result of an adverse event)…
- Trial name
- NCT06952075
- Testing
- GR1803
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.